english.prescrire.org > Spotlight > Archives : 2026 > Sotatercept (Winrevair°) in pulmonary arterial hypertension

Spotlight: Archives

Every month, the subjects in Prescrire’s Spotlight.

Sotatercept (Winrevair°) in pulmonary arterial hypertension

 Marketing Authorisations  Sotatercept has been authorised in the European Union for use in adults with pulmonary arterial hypertension, as an add-on to other drugs. Does sotatercept extend survival in these patients? Does it reduce functional impairment and slow disease progression? And what are its adverse effects?
Full article available for download by subscribers

 ©Prescrire 1 February 2026

Source: "Sotatercept (Winrevair°) in pulmonary arterial hypertension. Sometimes an option as an add-on to other drugs" Prescrire Int 2026; 35 (278): 33-35. Subscribers only.

Filet

Enjoy full access to Prescrire International, and support independent information